{"id":"NCT01211873","sponsor":"Guerbet","briefTitle":"Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions","officialTitle":"Safety and Efficacy Evaluation of DOTAREM® in Magnetic Resonance Imaging (MRI) in Patients With Central Nervous System (CNS) Lesions.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2011-11","completion":"2011-11","firstPosted":"2010-09-30","resultsPosted":"2014-05-29","lastUpdate":"2019-04-18"},"enrollment":416,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Diagnostic Self Evaluation","Central Nervous System Diseases"],"interventions":[{"type":"DRUG","name":"Dotarem (gadoterate meglumine)","otherNames":["Dotarem"]},{"type":"DRUG","name":"Magnevist (gadopentetate dimeglumine)","otherNames":["Magnevist"]}],"arms":[{"label":"Dotarem (gadoterate meglumine )","type":"EXPERIMENTAL"},{"label":"Magnevist (gadopentetate dimeglumine)","type":"ACTIVE_COMPARATOR"},{"label":"Dotarem 2 (gadoterate meglumine )","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to look at the safety (what are the side effects)and efficacy (how well does it work) of Dotarem® when used in taking images of the brain / spine. The results will be compared to the results of MRI taken without Dotarem.","primaryOutcome":{"measure":"MRI Lesion Visualization (Border Delineation, Internal Morphology and Contrast Enhancement) at Patient Level for Both \"Pre\" and \"Paired\" Evaluation","timeFrame":"up to 24 hours","effectByArm":[{"arm":"Dotarem (Gadoterate Meglumine) - PRE","deltaMin":1.06,"sd":1.23},{"arm":"Dotarem (Gadoterate Meglumine) - PAIRED","deltaMin":3.3,"sd":2.64}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":52,"countries":["United States","Argentina","Austria","Brazil","Chile","France","Germany","Italy","South Korea","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":240},"commonTop":["injection site pain","nausea","headache","injection site hematoma","extravasation"]}}